/ /

  • linkedin
  • Increase Font
  • Sharebar

    Long-term stability of ranibizumab shown in DME patients

    Orlando—In roughly 25% of patients, no further treatment was required to maintain mean visual acuity outcomes achieved at the exit of the RIDE/RISE 3-year core studies evaluating the efficacy of ranibizumab in patients with diabetic macular edema (DME), according to Allen Ho, MD.

    The open-label extension phase of the studies evaluated whether the efficacy and safety achieved with monthly ranibizumab was maintained with less-than-monthly treatment using a protocol-based regimen that allowed for more flexible dosing and visit intervals, said Dr. Ho, Wills Eye Institute, Philadelphia.

    In the core studies, patients with DME (n = 759) were randomly assigned to monthly 0.5 or 0.3 mg ranibizumab injected intravitreally or sham injection for 2 years. At that point, those in the sham group could cross over to receive active dosing. After month 36, patients (n = 500) who enrolled in the optional extension received open-label 0.5 mg ranibizumab regardless of prior randomization and to date, results are through month 54.

    “Overall, visual acuity outcomes were excellent, with visual gains gains achieved after 36 or 12 months of monthly ranibizumab maintained using less-than-monthly dosing,” Dr. Ho said.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results